Heavy Light Chain in Chronic Lymphocytic Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02377869|
Recruitment Status : Unknown
Verified February 2015 by tamar.tadmor, Bnai Zion Medical Center.
Recruitment status was: Recruiting
First Posted : March 4, 2015
Last Update Posted : March 4, 2015
Recently, a novel assay for detecting heavy/light chain (HLC) ratios has been reported which enables improvement in paraprotein detection and monitoring in multiple myeloma and other plasma-cell dyscrasias.
The prognostic and biological role of the HLC assay has as yet not been studied in CLL.
Aims of the proposed study:
- To quantify and analyze the prognostic significance of HLC ratios in the serum of CLL patients. (In addition to FLC)
- To study the different patterns of Immunoglobulin's subclass antibodies in the serum of patients with CLL and compare them to those of to healthy volunteers.
- To perform a sub-analysis in patients with CLL who have autoimmune phenomenon (AIHA and ITP)
|Condition or disease||Intervention/treatment|
|CLL||Other: No intervantion|
|Study Type :||Observational|
|Estimated Enrollment :||130 participants|
|Official Title:||Heavy Light Chain in Chronic Lymphocytic Leukemia|
|Study Start Date :||January 2015|
|Estimated Primary Completion Date :||January 2017|
|Estimated Study Completion Date :||January 2020|
- 1) To quantify and analyze the prognostic significance of HLC ratios in the serum of CLL patients. (In addition to FLC) [ Time Frame: 5 years ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02377869
|Bnai Zion Medical Center||Recruiting|
|Haifa, Israel, 31048|
|Contact: Tamar Tadmor, MD +97248359 ext 407 firstname.lastname@example.org|